The Beth Pathology 201 Lyons Ave BLDG EL, Newark, NJ 07112 9739267307 (phone), 9737058301 (fax)
Jersey City Medical Center Pathology Laboratory 355 Grand St STE 3, Jersey City, NJ 07302 2019152486 (phone), 2019152377 (fax)
Education:
Medical School Tianjin Med Univ, Tianjin City, Tianjin, China Graduated: 1988
Languages:
English
Description:
Dr. Lin graduated from the Tianjin Med Univ, Tianjin City, Tianjin, China in 1988. She works in Jersey City, NJ and 1 other location and specializes in Anatomic Pathology & Clinical Pathology. Dr. Lin is affiliated with Jersey City Medical Center and Newark Beth Israel Medical Center.
Seed Intellectual Property Law Group PLLC 701 5Th Ave Ste 5400, Seattle, WA 98104 2066224900
Licenses:
Washington - Active 2000
Experience:
Partner at Seed Intellectual Property Law Group - 2008-present Associate at Seed Intellectual Property Law Group - 2000-2007 Legal Intern at Washington State Attorney General's Office - 1998 Postdoctoral Fellow at University of Missouri-Columbia - 1996-1997 Research Scientist at Institute of Oceanology, Chinese Academy of Sciences - 1989-1991
Education:
University of Washington School of Law Degree - JD - Juris Doctor - Law Graduated - 2000 University of Missouri, Columbia Degree - PhD - Doctorate - Molecular Biology Graduated - 1996 Chinese Academy of Sciences Degree - MA - Masters - Plant Physiology Graduated - 1989 Lanzhou University Degree - BS - Bachelor of Science - Biology Graduated - 1986
Specialties:
Intellectual Property - 100%
Languages:
Mandarin
Associations:
American Bar Association American Intellectual Property Law Association Washington Biotechnology and Biomedical Association Washington State Bar Association
Syed Faiyaz Ahmed Hossainy - Hayward CA, US Yiwen Tang - San Jose CA, US Homayon Askaryar - Newark CA, US Qing Lin - Hayward CA, US Thierry Glauser - Redwood City CA, US
Assignee:
Advanced Cardiovascular Systems, Inc. - Santa Clara CA
International Classification:
A61F 2/82
US Classification:
424423
Abstract:
Methods for making coatings on an implantable device such as a drug-eluting stent comprising a polymer and nano or microparticles of a drug in slow-dissolving polymorph, implantable devices produced by the methods and methods of using the coatings are provided.
Thierry Nivaggioli - Los Altos CA, US Jane Shiah - Cupertino CA, US Qing Lin - Fremont CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61F013/00
US Classification:
424427000
Abstract:
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
Thierry NIVAGGIOLI - Los Altos Hills CA, US Jane Guo Shiah - Cupertino CA, US Qing Lin - Fremont CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61F 2/00 A61K 31/56 A61P 27/02
US Classification:
424428, 424427, 514180
Abstract:
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
Jane Guo Shiah - Irvine CA, US Qing Lin - Fremont CA, US
International Classification:
A61K 47/34
US Classification:
264145
Abstract:
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
- Irvine CA, US James Jane-Guo Shiah - Irvine CA, US Qing Lin - Fremont CA, US
International Classification:
A61K 9/00 A61K 31/573 A61K 47/34 A61K 31/57
Abstract:
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
- Irvine CA, US James Jane-Guo Shiah - Irvine CA, US Qing Lin - Fremont CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 9/00 A61K 47/34 A61K 31/573
Abstract:
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
th experiments employ a multiton volume of liquid xenon. Qing Lin of the University of Science and Technology of China and member of the PandaX Collaboration says that the result is an extremely important validation of the experiment. Detecting such a rare signal proves our ability to detect a dark
Date: Nov 07, 2024
Category: Science
Source: Google
PandaX sets new constraints on the search for light dark matter via ionization signals
"Currently, strong constraints exist for heavy mass dark matter candidates derived from null results in direct detection experiments using xenon detectors," Yue Meng, Qing Lin and Ning Zhou told Tech Xplore, on behalf of the PandaX collaboration. "However, traditional searches are not sensitive to l